FEF25%-75%

FEF25%–75%

Pulmonary medicine A clinical test that measures the forced expiratory flow from 25% to 75% of vital capacity, which was once thought to be one of the most sensitive, simplest, and least expensive methods for evaluating small airways disease
References in periodicals archive ?
This was supported by a post-hoc analysis of the TIGER-1 trial data, which showed a significant improvement relative to placebo in FEF25%-75% in a subgroup of patients (n=329) with baseline FEV1 110% predicted normal (p=0.
The potential of denufosol to reach the lung's small airways was supported by a post-hoc analysis of the TIGER-1 trial, which showed a significant improvement relative to placebo in FEF25%-75% (Forced Expiratory Flow) in a subgroup of patients (n=329) with baseline FEV1 (Forced Expiratory Volume in One Second) [?
The change from baseline for FEF25%-75% (Forced Expiratory Flow), a measure of small airways function, for the adolescent patients treated with denufosol at the Week 24 Endpoint was 115 mL/sec.
Denufosol was significantly more effective than placebo in improving FEF25%-75% in patients with 110% predicted FEV1 (p=0.
In the first study, the FEF25%-75% scores rose from a baseline average of 74.
Change from baseline in FEF25%-75% (Forced Expiratory Flow) at the Week 48 Endpoint, a measure of small airways function (-0.
One exception to this finding is the predicted values for FEF25%-75% which tend to be slightly lower, at least in comparison to some older studies.